KYNB
KYNTRA BIO, INC.
NASDAQ · Healthcare · Medical - Pharmaceuticals · US
$7.08
−0.35%Next report
Analyst consensus
- Next report date
- Nov 9, 2026
- EPS estimate
- -$3.73
- Revenue estimate
- $1.8M
Latest reported
- Last report date
- Aug 13, 2026
- EPS actual
- $2.96
- EPS estimate
- -$3.18
- Revenue actual
- -$1.5M
- Revenue estimate
- $2.1M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 7
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +47.2%
- Revenue beats (12Q)
- 5
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $40
- PT range
- $35 – $43
- Analysts
- 3
3 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 13, 2026 | -$3.18 | $2.96 | Beat 193.08% | -$1.5M |
| May 11, 2026 | -$3.36 | -$3.74 | Miss -11.31% | $3.7M |
| Mar 16, 2026 | -$3.88 | -$3.61 | Beat 7.08% | $1.3M |
| Mar 17, 2025 | -$0.08 | -$0.08 | In line | -$123.3M |
| Feb 26, 2024 | -$0.42 | -$0.57 | Miss -35.71% | $27.1M |
| Feb 27, 2023 | -$0.95 | -$0.70 | Beat 26.32% | $34.4M |
| Feb 28, 2022 | -$0.68 | -$1.45 | Miss -113.24% | $16.5M |
| Mar 1, 2021 | -$0.29 | -$0.64 | Miss -120.69% | $65.0M |
| Nov 5, 2020 | -$0.80 | $0.35 | Beat 143.75% | $44.0M |
| Aug 6, 2020 | -$0.59 | -$0.95 | Miss -61.02% | $42.9M |
| May 7, 2020 | -$0.30 | -$0.89 | Miss -196.67% | $24.4M |
| Mar 2, 2020 | -$0.62 | -$1.12 | Miss -80.65% | $8.0M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 9, 2026